Drugs / XJN010
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07156773 | Sep 2025 → Mar 2026 overdue | Parkinson disease | Guangzhou Novaken Pharm Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XJN010 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07156773 ↗ |
| Route | Intranasal | “The drug used is XJN010 Nasal Spray.” NCT07156773 ↗ |